← All trials
NCT06178991
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 21, 2023
- Primary completion
- Aug 30, 2024
- Completion date
- Aug 30, 2024
- First posted
- Dec 21, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 7500
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.